Abcam markets research-grade antibodies to academic and commercial users
and is headquartered in Cambridge, UK, with a US office in Cambridge,
Massachusetts. Its online catalogue of more than 17,000 products is
supported by continually updated technical data created by the Company.

* Abcam was founded in 1998 by Dr Jonathan Milner (Chief Executive Officer),
Dr David Cleevely (Chairman) and Prof Tony Kouzarides (Non-executive
Director).

* Abcam is rapidly growing, profitable and cash generative. In the year
ending 30 June 2005, Abcam reported sales of #12.1 million (2004: #6.72m)
and pre-tax profits of #2.98 million (2004: #1.45m). The Company expects
sales in the current financial year, ending 30 June 2006, to be no less
than #18.5 million and it intends to implement a progressive dividend
policy.

* As announced on 28 October 2005, #10 million, before expenses, has been
raised for Abcam via a placing of new shares at the price of 167 pence per
share (the "Placing Price"). A further #5.25 million, before expenses, has
been raised for selling shareholders via a placing of existing shares at
the Placing Price.

* At the Placing Price, the market capitalisation of Abcam is approximately
#57.5 million (post new money). Its now circa 70 million.

* The net proceeds of the placing available to Abcam will be used to develop
future growth opportunities including the expansion of the online
catalogue, the broadening of the customer base, the penetration of new
geographic markets and the possible acquisition of existing catalogues or
complementary product lines.

* Numis Securities Limited is the Company's nominated adviser and broker.

preliminary results for the 12 months ended 30 June 2008 on Tuesday 9 September 2008.

Interesting business, reading the brief notes here - but I don't understand why the sp is so robust, particualrly just recently... was a new product released about March08?
I must say I don't like this (high), sp and don't like such a high PE ratio, but that's me.

Tipped by The Naked Trader Robbie Burns on The Four Wise Monkeys. Website address below.

http://www.4wm.co.uk

The Board remains confident in the prospects for continued growth, tempered only by an appreciation that even though the Company should be reasonably resilient to any downturn the threat of global recession remains a risk for every business.

The Company will report its interim results for the six months ended 31 December 2008 in the week commencing 9 March 2009.

Abcam plc (AIM: ABC) announces that the Company's Annual Report and Accounts for the year ended 30 June 2008 has been posted to shareholders and may also be
viewed on, or downloaded from, the Company's website www.abcam.com.

NOW OVER 600p

17-Mar-09 David Douglas Cleevely SOLD 800,000 shares AT 575p 4,600,000.00

NOW OVER 700p

TIME TO SELL OR IS IT.

GOOD RESULTS

SOLDOUT TODAY CAP GAINS.

in 1587p

Abcam flying today. Soared past previous high, and then some.

The online catalog grew significantly both in primary antibodies and in new product areas and comprised 81,818 products at 31st December 2011, an increase of 18.3% on 31st December 2010. In addition, all 477 small molecule products from Ascent Scientific were launched on the catalog last week under the brand name ABCAM Biochemicals.

Haven't traded one of Robbie Burns tips for a while now, this one looks interesting. He has gone short @ 411.0 target 370 (then 330.0).

Sell order on the spreads left for 396.0 if triggered stop 430.0

Was beginning to think NT was losing his touch, albeit on low volume finally below 400.0